ABO-Matched Probiotic Bacteria for Gastrointestinal Colonization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current probiotic supplements are ineffective in promoting desired health effects for every individual due to a lack of personalization, as they do not account for variations in ABO blood group-specific bacterial adhesion and resistance to gastrointestinal conditions.

Innovation Solution

Development of probiotic bacteria strains with enhanced adhesion to ABO blood group antigens and improved resistance to acid and bile, characterized by specific adhesion and survival properties, allowing for personalized probiotic compositions and treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional probiotic supplements are used, then they are available for general use, but they are ineffective in promoting desired health effects for every individual due to lack of personalization

Engineering Contradiction:
Improvepersonalization effectivenessVSAvoidhealth effect consistency
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by selecting bacterial strains with specific adhesion properties tailored to individual ABO blood group types. Different strains are matched to specific blood group antigens (A, B, or O) to create personalized probiotic compositions that optimize colonization and health effects for each individual's biological characteristics

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by measuring and comparing adhesion properties of bacterial strains against specific ABO blood group antigens. Strains are selected based on quantitative adhesion data and resistance parameters to acid and bile, creating personalized formulations adjusted to individual biological parameters

Inventive Principle:
Principle #35Parameter changes

2Ease of manufacture

If probiotic bacteria are selected without ABO blood group consideration, then selection is simplified, but adhesion to mucosa and colonization efficiency are reduced

Engineering Contradiction:
Improvestrain selection processVSAvoidbacterial colonization density
Core Design Contradiction:
Ease of manufactureVSQuantity of substance

Solution Approach 1:

The patent employs parameter changes by using ABO blood group typing as a selection criterion for bacterial strains. The process involves determining an individual's blood group type and selecting strains with demonstrated adhesion to the corresponding blood group antigen, thereby optimizing colonization density through biologically relevant parameter matching

Inventive Principle:
Principle #35Parameter changes

3Reliability

If bacteria with enhanced ABO antigen adhesion are selected, then colonization and pathogen blocking are improved, but the complexity of strain selection and personalization increases

Engineering Contradiction:
Improvecolonization stabilityVSAvoidpersonalization system complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by matching specific bacterial strains to specific ABO blood group types (A, B, or O) based on demonstrated adhesion properties. This creates targeted probiotic compositions that optimize colonization stability for each individual's blood group, rather than using a one-size-fits-all approach

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent incorporates feedback mechanisms through adhesion assays that measure bacterial binding to ABO antigens. This quantitative feedback data is used to select and optimize strains for personalized compositions, ensuring reliable colonization while providing a systematic approach to managing complexity

Inventive Principle:
Principle #23Feedback

4Ease of manufacture

If probiotics are formulated without considering acid and bile resistance, then formulation is simpler, but survival in gastrointestinal tract is reduced

Engineering Contradiction:
Improveformulation processVSAvoidgastrointestinal survival
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent utilizes parameter changes by assessing and selecting bacterial strains based on their resistance parameters to acid and bile. These resistance characteristics are measured and used as selection criteria to ensure probiotic strains can survive the harsh gastrointestinal environment, thereby improving reliability without significantly complicating the formulation process

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The enhanced adhesion and survival properties of these strains improve colonization in the gastrointestinal tract, blocking pathogenic adhesion and providing longer-lasting health benefits, thereby effectively preventing and treating gastrointestinal disorders.

Implementation Method 1

certain bacterial strains showed enhanced in vitro adhesion to one or more of the ABO blood group antigens

Methodology Applied
Scientific EffectAdhesion: Adhesive

Implementation Method 2

These properties may be helpful to enable the bacterium or metabolite thereof to survive the conditions of the stomach and gastrointestinal tract

Methodology Applied
Scientific EffectAcid resistance:

Implementation Method 3

more than 40% average bile tolerance represented as growth in 0.9% dehydrated fresh bile

Methodology Applied
Scientific EffectBile resistance:

Data Source

PatentUS12419923B2Bacteria
Publication Date: 2025.09.23 INT N&H DENMARK APS

AI summary

The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.